Welcome to ASCO Connection Discussion

LOGIN TO START A DISCUSSION
Filter by Molecular Oncology Tumor Board
Molecular Oncology Tumor Board
ASCO University
Apr 12, 2017 9:01 AM
Read more to answer the following questions: 1) Would you recommend clinical genetics consultation for BRCA testing? Would an expanded panel be beneficial? 2) What would be the next step in this patient’s management? 3) Is there a value in performing biopsy of liver lesion before starting any...
Molecular Oncology Tumor Board
ASCO University
Mar 15, 2017 9:47 AM
Read more to answer the following questions:
1. Who should get routine molecular testing at the time of diagnosis of NSCLC and what genes should be included in the molecular panel?
2. What is the proper timing of testing and sequencing of available therapies?
3. What treatment options are available...
Molecular Oncology Tumor Board
ASCO University
Feb 15, 2017 8:30 AM
Read more to answer the following questions:
1.    Recognize the diagnosis of CML and importance of bone marrow biopsy at presentation.
2.    Apply considerations when choosing initial therapy.
3.    Recognize when to switch therapy when response is suboptimal.
4.    Identify how to treat...
Molecular Oncology Tumor Board
ASCO University
Jan 11, 2017 2:00 PM
Read more to answer the following questions: 1) Which tests are the most appropriate in identifying a BRAF codon 600 mutation for potential FDA-targeted treatment? 2) What is the significance of the CDKN2A mutation? 3) If systemic therapy is selected, would you be more inclined to offer targeted...
Molecular Oncology Tumor Board
ASCO University
Dec 07, 2016 8:16 AM
Read more to answer the following questions:
Is further tissue needed to confirm radiologically presumed metastatic disease or for repeat HER2 testing? What systemic therapy option would you recommend for confirmed HER2 negative metastatic gastric cancer?

Pages

Tweets from ASCO

Tweets from Oncology Community